

PUBLIKATIONSVERZEICHNIS

Originalarbeiten

Wang J, Weiss T, Neidert MC, Toussaint NC, Naghavian R, Moreno Sellés C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin JH, McKay R, Wu CJ, Lutterotti A, Sospedra M, Moch H, Greiner EF, Bodenmiller B, Regli L, Weller M, **Roth P**, Martin R. Vaccination with designed neopeptides induces intratumoral, crossreactive CD4+ T cell responses in glioblastoma. *Clin Cancer Res* 2022, *in press*

Lassman AB, Sepúlveda-Sánchez JM, Cloughesy T, Gil Gil MJ, Puduvalli VK, Raizer J, De Vos FY, Wen PY, Butowski N, Clement PM, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, **Roth P**. Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. *Clin Cancer Res* 2022, *in press*

Rösler W, Bink A, Bissig M, Imbach L, Marques Maggio E, Manz MG, Müller T, **Roth P**, Rushing E, Widmer C, Zenz T, von Moos S, Müller AMS. CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS. *Hemasphere* 2022;6(7):e733

Meister H, Look T, **Roth P**, Pascolo S, Sahin U, Lee S, Hale BD, Snijder B, Regli L, Ravi V, Heiland DH, Sentman CL, Weller M, Weiss T. Multifunctional mRNA-based CAR T cells display promising anti-tumor activity against glioblastoma. *Clin Cancer Res* 2022, *in press*

Hertler C, Seystahl K, Le Rhun E, Wirsching HG, Roth P, Weller M, Gramatzki D. Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab. *Neuro Oncol*, *in press*

Wolpert W, Grossenbacher B, Moors S, Lareida A, Serra C, Akeret K, **Roth P**, Imbach L, Le Rhun E, Regli L, Weller M, Galovic M. Post-operative progression of brain metastasis is associated with seizures. *Epilepsia*, *in press*

Eisele A, Seystahl K, Rushing E, **Roth P**, Le Rhun E, Weller M, Gramatzki D. Venous thromboembolic events in glioblastoma patients: an epidemiological study. *Eur J Neurol* 2022, *in press*

Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, **Roth P**, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial. *Neuro Oncol* 2022, *in press*

Le Rhun E, Devos P, Winklhofer S, Lmalen H, Brandsma D, Kumthekar P, Castellano A, Compter A, Dhermain F, Franceschi E, Forsyth P, Furtner J, Galldiks N, Gállego

Pérez-Larraya J, Gempt J, Hattingen E, Hempel JM, Lukacova S, Minniti G, O'Brien B, Postma TJ, **Roth P**, Rudà R, Schaefer N, Schmidt NO, Snijders TJ, Thust S, van den Bent M, van der Hoorn A, Vogin G, Smits M, Tonn JC, Jaeckle K, Preusser M, Glantz M, Wen PY, Bendzus M, Weller M. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. *Neuro Oncol* 2022, *in press*

Togni C, Rom E, Burghardt I, **Roth P**, Rushing EJ, Weller M, Gramatzki D. Prognostic relevance of transforming growth factor- β receptor expression and signaling in glioblastoma, isocitrate dehydrogenase-wildtype. *J Neuropath Exp Neurol* 2022, *in press*

Ahmadov U, Picard D, Bartl J, Silginer M, Trajkovic-Arsic M, Qin N, Wolter M, Lim JK, Pauck D, Winkelkotte AM, Melcher M, Langini M, Blümel L, Marquardt V, Sander F, Stefanski A, Steltgens S, Hassiepen C, Kaufhold A, Meyer FD, Seibt A, Kleinesudeik L, Hain A, Münk C, Knobbe-Thomsen C, Schramm A, Fischer U, Leprivier G, Stühler K, Fulda S, Siveke J, Distelmaier F, Borkhardt A, Weller M, **Roth P**, Reifenberger G, Remke M. The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. *Cell Death Dis* 2021;12:885

Wirsching HG, Steiner L, Becker D, Regli L, Andratschke N, Kulcsar Z, **Roth P**, Weller M. Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. *Neuro Oncol* 2021;23:1612-1613

Mastall M, Wolpert F, Gramatzki D, Imbach L, Becker D, Schmick A, Hertler C, **Roth P**, Weller M, Wirsching HG. Survival of brain tumour patients with epilepsy. *Brain* 2021;144:3322-3327

Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, **Roth P**, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Reifenberger G. TERT promoter mutation and MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: is there a link? *Eur J Cancer* 2021;147:84-94

Gramatzki D, Felsberg J, **Roth P**, Kaulich K, von Deimling A, Rushing EJ, Reifenberger G, Weller M. The molecular evolution of glioblastoma treated by gross total resection alone. *Neuro Oncol* 2021;23:334-336

Gramatzki D, Felsberg J, Hentschel B, Bähr O, Westphal M, Schackert G, Tonn JC, Herrlinger U, Loeffler M, Pietsch T, Steinbach JP, Reifenberger G, **Roth P**, Weller M. Chemotherapy for adult patients with spinal cord gliomas. *Neurooncol Pract* 2021;8:475-484.

Wirsching HG, Roelcke U, Weller J, Hundberger T, Hottinger AF, von Moos R, Caparrotti F, Conen K, Remonda L, **Roth P**, Ochsenein A, Tabatabai G, Weller M. MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in IDH wild-type glioblastoma: the randomized ARTE trial. *Clin Cancer Res* 2021;27:179-188

Weiss T, Puca E, Silginer M, Hemmerle T, Pazahr S, Bink A, Weller M, Neri D, **Roth P**. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. *Sci Transl Med* 2020;12(564):eabb2311

Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, **Roth P**, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwiertes R, Sampson J, Weller M. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma. The CheckMate 143 phase 3 randomized clinical trial. *JAMA Oncol* 2020;6:1003-1010

Wolpert F, Kulcszar Z, Hänsel M, Rushing E, Seystahl K, Schweizer J, **Roth P**, Luft AR, Wegener S, Weller M. Embolization of tumor cells is rare in patients with systemic cancer and cerebral large vessel occlusion. *Eur J Neurol* 2020;27:2041-2046

Wolpert F, Berghoff AS, Grossenbacher B, Lareida A, **Roth P**, Neidert MC, Andratschke N, Le Rhun E, Preusser M, Weller M. Venous thromboembolic events in patients with brain metastases: the PICOS score. *Eur J Cancer* 2020;134:75-85

Gramatzki D, Rogers JL, Neidert M, Hertler C, Le Rhun E, **Roth P**, Weller M. Antidepressant drug use in glioblastoma patients: an epidemiological view. *Neurooncol Pract* 2020;7:514-521

Lohmann B, Silginer M, Picard D, Schneider H, Remke M, **Roth P**, Reifenberger G, Weller M. Interferon- β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. *Neuro-Oncol Adv* 2020;2(1):vdaa043

Hertler C, Eisele G, Gramatzki D, Seystahl K, Wolpert F, **Roth P**, Weller M. End-of-life care for glioma patients; the caregivers' perspective. *J Neurooncol* 2020;147:663-669

Wirsching HG, Morel C, **Roth P**, Weller M. Socioeconomic burden and quality of life in meningioma patients. *Qual Life Res* 2020;29:1801-1808

Wolpert F, Lareida A, Terziev R, Grossenbacher B, Neidert MC, **Roth P**, Poryazova R, Imbach L, Le Rhun E, Weller M. Risk factors for the development of epilepsy in patients with brain metastasis. *Neuro Oncol* 2020;22:718-728

Papachristodoulou A, Silginer M, Weller M, Schneider H, Hasenbach K, Janicot M, **Roth P**. Therapeutic targeting of TGF- β ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. *Clin Cancer Res* 2019;25:7189-7201

Wolpert F, Lareida A, Terziev R, Grossenbacher B, Andratschke N, **Roth P**, Rohrman S, Stahel R, Guckenberger M, Le Rhun E, Weller M. Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. *J Neurooncol* 2019;145:339-347

Zhu Y, Weiss T, Zhang Q, Sun R, Wang B, Wu Z, Zhong Q, Yi X, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C, Schmid M, Rutishauser D, Ljubicic J, Christiansen A, Fritz C, Rupp N, Poyet C, Rushing E, Weller M, **Roth P**, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L,

Wild P, Aebersold R, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol Oncol* 2019;13:2305-2328

Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, **Roth P**, Snijders TJ, Winkler F, Winklerhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, van den Bent M, Wen PY, Bendszus M, Weller M on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal. *Neuro Oncol* 2019;21:648-658

Papachristodoulou A, Signorell RD, Werner B, Brambilla D, Luciani P, Cavusoglu M, Grandjean J, Silginer M, Rudin M, Martin E, Weller M, **Roth P***, Leroux JC*. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. *J Control Release* 2019;295:130-139 (**corresponding author & shared senior authorship*)

Eisele G, Roelcke U, Conen K, Huber F, Weiss T, Hofer S, Heese O, Westphal M, Hertler C, **Roth P**, Weller M. Complementary and alternative medicine use by glioma patients in Switzerland. *Neurooncol Pract* 2019;6:237-244

Çavuşoğlu M, Zhang J, Ielacqua G, Pellegrini G, Signorell RD, Papachristodoulou A, Brambilla D, **Roth P**, Weller M, Rudin M, Martin E, Leroux JC, Werner B. Closed-loop cavitation control for focused ultrasound-mediated blood-brain barrier opening by long-circulating microbubbles. *Phys Med Biol* 2019;64:045012

Turner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, **Roth P**, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M. Hyper N-glycosylated SAMD14 and Neurabin-I as Driver CNS Autoantigens of PCNSL. *Blood* 2018;132:2744-2753

Schuster H, Shao W, Weiss W, Pedrioli P, **Roth P**, Weller M, Campbell DS, Deutsch EW, Moritz RL, Planz O, Rammensee HG, Aebersold R, Caron E. A tissue-based draft map of the murine MHC class I immunopeptidome. *Sci Data* 2018;5:180157

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, **Roth P**, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenein A, Weller M. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. *Ann Oncol* 2018;29:1423-1430

Gramatzki D, **Roth P**, Rushing EJ, Weller J, Andratschke N, Hofer S, Korol D, Regli L, Pangalu A, Pless M, Oberle J, Bernays R, Moch H, Rohrman S, Weller M. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. *Ann Oncol* 2018;29:1431-1436

Wolpert F, Weller M, Berghoff AS, Rushing E, Füreder LM, Petyt G, Leske H, Andratschke N, Regli L, Neidert MC, Stupp R, Stahel R, Dummer R, Frauenfelder T, **Roth P**, Reyns N, Kaufmann PA, Preusser M, Le Rhun E. Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography (FDG)-PET/CT for patients with brain metastasis from unknown primary site. *Eur J Cancer* 2018;96:64-72

Weiss T, Weller M, Guckenberger M, Sentman CL, **Roth P**. NKG2D-based CAR-T cells and radiotherapy exert synergistic efficacy in glioblastoma. *Cancer Res* 2018;78:1031-1043

Neidert MC, Kowalewski DJ, Silginer M, Kopolou K, Backert L, Peper JK, Marcu A, Freudenmann L, Wang S, Stickel S, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, **Roth P**, Regli L, Stevanovic S, Weller M, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: Antigen discovery for T-cell based immunotherapy. *Acta Neuropathol* 2018;135:923-938

Happold C, Stojcheva N, Silginer M, Weiss T, **Roth P**, Reifenberger G, Weller M. Transcriptional control of O6-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. *J Neurochem* 2018;144:780-790

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, **Roth P**, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol* 2018;4:495-504

Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, Weller M, **Roth P**. NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma. *Clin Cancer Res* 2018;24:882-895

Signorell RD, Papachristodoulou A, Xiaoa J, Arpagausa B, Casalini T, Grandjean J, Thamm J, Steiniger F, Luciana P, Brambilla D, Werner B, Martin E, Weller M, **Roth P**, Leroux JL. Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. *Int J Pharm* 2018;536:388-396

Herrlinger U, Schäfer N, Fimmers F, Griesinger F, Rauch M, Kirchen H, **Roth P**, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. *J Cancer Res Clin Oncol* 2017;143:1815-1821

Silginer M, Nagy S, Happold C, Schneider H, Weller M, **Roth P**. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. *Neuro Oncol* 2017;19:1338-1349

Seystahl K, Papachristodoulou A, Burghardt I, Schneider S, Hasenbach K, Janicot M, **Roth P**, Weller M. Biological role and therapeutic targeting of TGF- β 3 in glioblastoma. *Mol Cancer Ther* 2017;16:1177-1186

Silginer M, Weller M, Stupp R, **Roth P**. Biological activity of tumor-treating fields (TTFields) in preclinical glioma models. *Cell Death Dis* 2017;8:e2753

Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. *Neuro Oncol* 2017;19:454-456

Weller M, **Roth P**, Sahm F, Burghardt I, Schuknecht B, Rushing EJ, Regli L, Lindemann JP, von Deimling A. Durable control of metastatic AKT1-mutant WHO grade I meningothelial meningioma by the AKT inhibitor, AZD5363. *J Natl Cancer Inst* 2017;109:1-4

Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß EK, Weiler M, Baer B, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein H, **Roth P**, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W. Prognostic relevance of miRNA-155 methylation in anaplastic glioma. *Oncotarget* 2016;7:82028-82045

Wick W, **Roth P**, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *Neuro Oncol* 2016;18:1529-1537

Burgett ME, Lathia JD, **Roth P**, Nowacki AS, Galileo DS, Pugacheva E, Huang P, Vasani A, Li M, Byzova T, Mikkelsen T, Bao S, Rich JN, Weller M, Gladson CL. Direct contact with perivascular tumor cells enhances integrin $\alpha\beta3$ signaling and migration of endothelial cells. *Oncotarget* 2016;7:43852-43867

Strehlow F, Bauer S, Martus P, Weller M, **Roth P**, Schlegel U, Seidel S, Scheibenbogen C, Korfel A, Kreher S. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. *J Neurooncol* 2016;129:165-171

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJB, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, **Roth P**, Golfopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). *Clin Cancer Res* 2016;22:4797-4806

Gramatzki D, **Roth P**, Felsberg J, Hofer S, Rushing EJ, Hentschel B, Westphal M, Krex D, Simon M, Schnell O, Wick W, Reifenberger G, Weller M. Chemotherapy for intracranial ependymoma in adults. *BMC Cancer* 2016;16:287

Gramatzki D, Dehler S, Rushing EJ, Zaugg K, Hofer S, Yonekawa Y, Bertalanffy H, Valavanis A, Korol D, Rohrmann S, Pless M, Oberle J, **Roth P**, Ohgaki H, Weller M.

Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009). *Cancer* 2016;122:2206-2215

Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, **Roth P**, Wick W, Goodman S, Hegi M, Picard M, Moch H, Straub J, Stupp R. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. *Oncotarget* 2016;7:15018-15032

Codo P, Weller M, Kaulich K, Schraivogel S, Silginer M, Reifenberger G, Meister G, **Roth P**. Control of glioma cell migration and invasiveness by GDF-15. *Oncotarget* 2016;7:7732-7746

Stojcheva N, Schechtmann G, Sass S, **Roth P**, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis FJ, Weller M, Reifenberger G, Happend C. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. *Oncotarget* 2016;7:12937-12950

Backes C, Meder B, Hart M, Ludwig N, Leidinger P, Vogel B, Galata V, **Roth P**, Menegatti J, Grässer F, Ruprecht K, Kahraman M, Grossmann T, Haas J, Meese E, Keller A. Prioritizing and selecting likely novel miRNAs from NGS data. *Nucleic Acids Res* 2016;44:e53

Happend C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, **Roth P**, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Do valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. *J Clin Oncol* 2016; 34:731-739

Roelcke U, Wyss MT, Nowosielski M, Rudà R, **Roth P**, Hofer S, Galldiks N, Crippa F, Weller M, Soffietti R. Amino acid PET to monitor chemotherapy response, and to predict seizure control and progression-free survival in WHO grade II gliomas. *Neuro Oncol* 2016;18:744-751

Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske H, Rushing EJ, Hao N, Platten M, Weller M, **Roth P**. The aryl hydrocarbon receptor links integrin signaling to the TGF- β pathway. *Oncogene* 2016;35:3260-3271

Hundsberger T, Hottinger AF, Roelcke U, **Roth P**, Migliorini D, Dietrich PY, Conen K, Pesce G, Hermann E, Pica A, Gross MW, Brügge D, Plasswilm L, Weller M, Putora PM. Patterns of care in recurrent glioblastoma in Switzerland - a multicentre national approach based on diagnostic nodes. *J Neurooncol* 2016;126:175-178

Wolpert F, Happend C, Reifenberger G, Florea AM, Deenen R, **Roth P**, Lamszus K, Westphal M, Neidert M, Weller M, Eisele G. Interferon- β modulates the innate immune response against glioblastoma initiating cells *PLoS ONE* 2015;10:e0139603

Tonder M, Weller M, Eisele G, **Roth P**. Carboplatin and etoposide in heavily pre-treated patients with progressive high-grade glioma. *Chemotherapy* 2015;60:375-378

Kreher S, Jöhrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, **Roth P**, Thiel E, Pietsch T, Weller M, Korfel A. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. *Neuro Oncol* 2015;17:1016-1021

Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen V, Barrie M, **Roth P**, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M. Phase I dose-escalation study of the anti-placental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. *Neuro Oncol* 2015;17:1007-1015

Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M. Differentially regulated miRNAs as prognostic biomarkers in the blood of PCNSL patients. *Eur J Cancer* 2015;51:382-90

Korfel A, Thiel E, Martus P, Möhle R, Griesinger R, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsbarger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, **Roth P**, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. *Neurology* 2015;84:1242-1248

Kreher S, Strehlow F, Martus P, **Roth P**, Hertenstein B, Röth A, Birnbaum T, Griesinger F, Rauch M, Kanz L, Thiel E, Weller M, Korfel A. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. *Ann Hematol* 2015;94:409-14

Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G, **Roth P**. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. *Oncotarget* 2014;5:7651-7662

Ahmad M, Frei K, Willscher E, Stefanski A, Kaulich K, **Roth P**, Stühler K, Reifenberger G, Binder H, Weller M. How stem-like are sphere cultures from long-term cancer cell lines: lessons from mouse glioma models. *J Neuropathol Exp Neurol* 2014;73:1062-1077

Wiestler B, Capper D, Sill M, Jones DTW, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiss EK, Schliesser MG, Radbruch A, Herold-Mende C, **Roth P**, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W. Integrated epigenetic and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathol* 2014;128:561-571

Tonder M, Eisele G, Weiss T, Hofer S, Seystahl K, Valavanis A, Stupp R, Weller M, **Roth P**. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. *Acta Oncol* 2014;53:1436-1440

Happold C, **Roth P**, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G, Weller M. Interferon- β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. *Mol Cancer Ther* 2014;13:948-961

Silginer M, Weller M, Ziegler U, **Roth P**. Integrin inhibition promotes atypical anoikis in glioma cells. *Cell Death Dis* 2014;23;5:e1012

Tonder M, Rushing EJ, Grotzer M, Sürücü O, Valavanis A, Buck A, Weller M, **Roth P**. Clinical reasoning: A 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades. *Neurology* 2014;82:e56-60

Rossetti AO, Jeckelmann S, Novy J, **Roth P**, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. *Neuro Oncol* 2014;16:584-588

Vogetseder A, Thies S, Ingold B, **Roth P**, Weller M, Schraml P, Goodman SL, Moch H. α v-integrin isoform expression in primary human tumors and brain metastases. *Int J Cancer* 2013;133:2362-2371

Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor- β pathway in glioblastoma. *Brain* 2013;136:564-576

Weller M, Martus P, **Roth P**, Thiel E, Korfel A, for the German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. *Neuro Oncol* 2012;14:1481-1484

Wolpert F, **Roth P**, Lamszus K, Tabatabai G, Weller M, Eisele G. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. *J Neuroimmunol* 2012;250:27-34

Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Röth A, Kaun S, Thiel E, Korfel A, Weller M. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG1 trial. *Neurology* 2012;79:890-896

Happold C, **Roth P**, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. *J Neurochem* 2012;122:444-455

Korfel A, Weller M, Martus P, **Roth P**, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundesberger T, Leithäuser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L. No prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. *Ann Oncol* 2012;23:2374-2380

Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. *J Neurochem* 2011;118:449-457

Eisele G, **Roth P**, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W, Weller M. APO010, a synthetic hexameric CD95 ligand, induces glioma cell death in vitro and in vivo. *Neuro Oncol* 2011;13:155-164

Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. *Clin Cancer Res* 2010;16:3851-3859

Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, **Roth P**, Nemets A, Shalom E, Ben-Yehuda D, Siegal T. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. *Blood* 2010;115:5005-5011

Miller J, Eisele G, Tabatabai G, Aulwurm S, von Kurthy G, Stitz L, **Roth P**, Weller M. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. *J Neurosurg* 2010;113:280-285

Kurzwelly D, Glas M, **Roth P**, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. *J Neurooncol* 2010;97:389-392

Roth P, Kissel M, Herrmann C, Eisele G, Leban J, Weller M, Schmidt F. SC68896, a novel small molecule proteasome inhibitor, exerts anti-glioma activity in vitro and in vivo. *Clin Cancer Res* 2009;15:6609-6618

Roth P, Zumsteg D. Seizure-induced periorbital petechial rash. *Eur Neurol* 2009;61:317

Roth T, Sokolov AN, Messias A, **Roth P**, Weller M, Trauzettel-Klosinski S. Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. *Neurology* 2009;72:324-331

Happold C, **Roth P**, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. *J Neurooncol* 2009;92:45-48

Happold C, Ernemann U, **Roth P**, Wick W, Weller M, Schmidt F. Anticoagulation for radiation-induced neurotoxicity revisited. *J Neurooncol* 2008;90:357-362

Roth P, Happold C, Eisele G, Nägele T, Weller M, Luft AR. A series of patients with subpial hemorrhage: clinical manifestation, neuroradiological presentation and therapeutic implications. *J Neurol* 2008;255:1018-1022

Weinmann L, Wischhusen J, Demma MJ, Naumann U, **Roth P**, DasMahapatra B, Weller M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. *Cell Death Differ* 2008;15:718-729

Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M. Malignant glioma cells counteract anti-tumor immune responses through expression of lectin-like transcript-1. *Cancer Res* 2007;67:3540-3544

Roth P, Aulwurm S, Gekel I, Beier D, Sperry RG, Mittelbronn M, Meyermann R, Beaman KD, Weller M, Wischhusen J. Regeneration and tolerance factor: a novel mediator of glioblastoma-mediated immunosuppression. *Cancer Res* 2006;66:3852-3858

Eckhardt K*, **Roth P***, Gunter T, Schmidt S, Feuerstein TJ. Differential effects of K(ATP) channel blockers on [(3)H]-noradrenaline overflow after short- and long-term

exposure to (+)-oxaprotiline or desipramine. *Naunyn Schmiedebergs Arch Pharmacol* 2003;367:168-175 (*gemeinsame Erstautorenschaft)

Buchbeiträge

Roth P, Yanez L, Mao Y, Ligon KL. Melanocytic tumors. In: Batchelor T, Weller M (eds.): *Oxford Textbook of Neuro-Oncology*, 2nd edition. Oxford University Press 2022; *in press*

Wolpert F, **Roth P**. Safety, tolerability, and use of steroids. In: Ahluwalia M, Metellus P, Soffiatti R (eds.): *Central Nervous System Metastases*. Springer, 2020, chapter 10

Roth P, Weller M. Peptide-specific vaccines. In: Sampson JH (ed.): *Translational immunotherapy of brain tumors: an update in basic immunology, translational immunotherapy and clinical trials*. Elsevier, 2017; pp 213-227

Roth P, Weller M. microRNAs in primary brain tumors: functional impact and potential use for diagnostic purposes. In: Keller A, Meese E (eds.): *Nucleic acids as molecular diagnostics*. Wiley-VCH, 2014; pp 25-37

Roth P, Eisele G, Weller M. Immunology of brain tumors. In: Grisold W, Soffiatti R. (eds.): *Handbook of Clinical Neurology; Volume Neurooncology*, 2012;104:45-51

Roth P. Prevention of infection in cancer patients. In: Greene JN (ed.): *Infections in cancer patients*. Dekker, New York, 2004; pp 477-495

Übersichtsarbeiten und Kommentare

Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, **Roth P**, Rudà R, Schlegel U, Soffiatti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC. European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL). *Neuro Oncol*, *in press*

Roth P, Winklhofer S, Müller AM, Dummer R, Mair MJ, Gramatzki D, Le Rhun E, Manz MG, Weller M, Preusser M. Neurological complications of cancer immunotherapy. *Cancer Treat Rev* 2021;97:102189

Wirsching HG, Weller M, Balabanov S, **Roth P**. Targeted therapies and immune checkpoint inhibitors in primary CNS lymphoma. *Cancers* 2021; 13:3073

Hofer S, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Pflugshaupt T, Eggenberger N, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Hans-Georg W, Wolpert F, **Roth P**, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). *Swiss Med Wkly* 2021;16;151:w20501.

Roth P, Pace A, Le Rhun E, Weller M, Ay C, Cohen-Jonathan Moyal E, Coomans M, Giusti R, Jordan K, Nishikawa R, Winkler F, Hong JT, Ruda R, Villà S, Taphoorn MJ, Wick W, Preusser M, on behalf of the EANO Executive Board and ESMO Guidelines Committee. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. *Ann Oncol* 2021;32:171-18

Roth P. Neuro-Oncology Practice in 2021: Covid-19, telemedicine, and beyond. *Neurooncol Pract*. 2021;8:107-108.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi M, Jakola A, Platten M, **Roth P**, Rudà R, Short S, Smits M, Taphoorn M, von Deimling A, Westphal M, Soffiatti R, Reifenberger G, Wick W. European Association of Neuro-Oncology (EANO) guideline on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol* 2021;18:170-186

Wirsching HG, **Roth P**, Weller M. A vasculature-centric approach to developing novel treatment options for glioblastoma. *Expert Opin Ther Targets* 2021;25:87-100

Roth P, Mason WP, Richardson PG, Weller M. Proteasome inhibition for the treatment of glioblastoma. *Expert Opin Investig Drugs* 2020;29:1133-1141

Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellingshoff IK, Minniti G, Nathanson D, Platten M, Preusser M, **Roth P**, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro Oncol* 2020;22:1073-1113

Roth P, Hottinger AF, Hundsberger T, Läubli H, Schucht P, Reinert M, Mamot C, Roelcke U, Pesce G, Hofer S, Weller M. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. *Swiss Med Wkly* 2020;150:w20256

Le Rhun E, Preusser M, **Roth P**, Reardon D, van den Bent MJ, Wen P, Reifenberger G, Weller M. Molecular targeted therapy of glioblastoma. *Cancer Treat Rev* 2019;80:101896

Weller M, Le Rhun E, Preusser M, Tonn JC, **Roth P**. How we treat glioblastoma. *ESMO Open* 2019;4(Suppl 2):e000520

Rudà R, Reifenberger G, Frappaz D, Pfister SM, Laprie A, Santarius T, **Roth P**, Tonn JC, Soffiatti R, Weller M, Cohen-Jonathan Moyal E. EANO guidelines for the diagnosis and treatment of endopial tumors. *Neuro Oncol* 2018;20:445-456

Wirsching HG, Weiss T, **Roth P**, Weller M. Basic principles of diagnosis and treatment of gliomas. *Nervenarzt* 2018;89:692-698

Weller M, **Roth P**, Preusser M, Wick W, Reardon D, Platten M, Sampson J. Vaccine-based immunotherapeutic approaches to gliomas and beyond. *Nat Rev Neurol* 2017;13:363-374

Roth P, Gramatzki D, Weller M. Management of elderly patients with glioblastoma. *Curr Neurol Neurosci Rep* 2017;17:35

Mangani D, Weller M, **Roth P**. The network of immunosuppressive pathways in glioblastoma. *Biochem Pharmacol* 2017;130:1-9

Weiss T, Weller M, **Roth P**. Immunological effects of chemotherapy and radiotherapy against brain tumors. *Expert Rev Anticancer Ther* 2016;16:1087-1094

Roth P, Preusser M, Weller M. Immunotherapy of brain cancer. *Oncol Res Treat* 2016;39:326-334

Seystahl K, Gramatzki D, **Roth P**, Weller M. Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. *Expert Opin Pharmacother* 2016;17:1259-1270

Gulden-Sala W, **Roth P**, Brown M, Andratschke N, Weller M, Stupp R. Gliomas – What I have to know in ten questions. *Praxis* 2016;105:330-337

Weiss T, Weller M, **Roth P**. Immunotherapy for glioblastoma: concepts and challenges. *Curr Opin Neurol* 2015;28:639-646

Wirsching HG, Happold C, **Roth P**, Weller M. Management of diffusely infiltrating glioma in the elderly. *Curr Opin Oncol* 2015;27:502-509

Preusser M, **Roth P**. New frontiers in neurooncology. *Curr Opin Neurol* 2015;28:626-627

Roth P, Weller M. Management of neoplastic meningitis. *Chin Clin Oncol* 2015;4:26

Roth P, Weller M. Chemotherapy of brain tumors in adults. *Nervenarzt* 2015;86:495-505

Roth P, Happold C, Weller M. Corticosteroid use in Neuro-Oncology: an update. *Neuro Oncol Pract* 2015;2:6-12

Roth P, Hoang-Xuan K. Challenges in the treatment of elderly patients with primary CNS lymphoma. *Curr Opin Neurol* 2014;27:697-701

Roth P, Weller M. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. *Neuro Oncol*, 2014;16:viii14-viii19

Hundsberger T, **Roth P**, Roelcke U. Neurological complications in cancer patients. *Praxis* 2014;103:1009-1016

Brown M, **Roth P**. Oligodendrogliome. info@onkologie 2014;2:24-26

Roth P, Stupp R, Eisele G, Weller M. Treatment of Primary CNS Lymphoma. Curr Treat Options Neurol 2014;16:277

Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Rev Anticancer Ther 2013;13:1319-1325

Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Curr Treat Options Oncol 2013;14:505-13

Serra A, Bonny O, Bürki S, Dorn T, Fuster D, Guzman R, Hofbauer G, Jenny B, Kätterer C, Plecko-Startinig B, Weibel L, **Roth P**, Steinlin M, Wohlrab G, Dill P. Tuberoöse Sklerose: Pathogenese, Klinik und neue Therapieansätze. Schweiz Med Forum 2013;13:696-702

Roth P, Hundsberger T, Tabatabai G, Weller M. Hirntumoren bei älteren Patienten: Fatal oder fataler Fatalismus? info@onkologie 2012;6:8-10

Roth P, Martus P, Korfel A, Weller. Pathogenesis and management of primary central nervous system lymphoma. Expert Rev Anticancer Ther 2012;12:623-633

Weller M, Platten M, **Roth P**, Wick W. Geriatric neuro-oncology: from mythology to biology. Curr Opin Neurol 2011;24:599-604

Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side effects. Curr Opin Neurol 2010;23:597-602

Wick W, **Roth P**, Wick A, Weller M. Was gibt es Neues in der Neuroonkologie? Akt Neurol 2010;37:454-460

Roth P, Weller M. Comment on: Dendritic cell and peptide based vaccination strategies for glioma. Neurosurgical Review 2009;32:273

Eisele G, **Roth P**, Wick W, Weller M. MGMT in der klinischen Praxis. Onkologie heute 2008;4:32-39

Roth P, Weller M. Niedriggradige primäre ZNS-Lymphome: weniger aggressive Therapieansätze sind gerechtfertigt, InFo Neurologie 2006; Sonderheft 1